The drug, JSKN003, showed promising early efficacy in colorectal cancer patients in China in a Phase I/II trial.

Intellia disclosed that a patient treated with nexiguran ziclumeran as part of the Phase III MAGNITUDE trial has been hospitalized.

Novartis will acquire the firm's neuroscience assets. Meanwhile, Avidity will separate and transfer its precision cardiology programs to a subsidiary.

In the small first-in-human study, AB-1002 showed an encouraging safety profile and early signs of efficacy, investigators ...

In the study, researchers molecularly screened nearly 2,000 cancer patients and matched 14 percent into a study arm.

A man with neurofibromas who didn't know he's been clinically diagnosed with NF1, learns he harbors a deeply intronic, likely ...

Amid steady Q3 growth, Roche's giredestrant-Afinitor combo extended survival in advanced ER-positive, HER2-negative early breast cancer.

In two Phase I trials, researchers safely administered CAR T cells to high-grade glioma patients and are exploring ways to ...

The firm also said this week it will conduct a pivotal study next year of its PRMT5 inhibitor in MTAP-deleted pancreatic cancer.

In a Phase II trial, 23 percent of patients achieved complete remission plus complete remission with partial hematologic recovery on Revuforj.

Triple-negative breast cancer patients on Keytruda had significantly improved response rates compared to chemo, despite taking one-tenth the standard dose.

NEW YORK – BioNTech said Wednesday that it began an exchange offer to complete its $1.25B all-stock acquisition of mRNA immunotherapy developer CureVac in a deal that was announced in June.